Shanghai, China, 11 June 2025 - MicroPort® CardioFlow recently announced a series of important developments for its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system and Alwide® Plus balloon catheter, marking expanded access and regulatory progress in key global markets.
In Lisbon, Portugal, the VitaFlow Liberty® system was successfully used for its first commercial implantation at Hospital de Santa Cruz, led by Dr. Rui Teles and his team. The procedure was completed without complications or paravalvular leakage, representing a significant step forward for the system’s adoption in Europe. Portugal is the eighth European country where VitaFlow Liberty® has entered the commercial market.
In Brazil, the VitaFlow Liberty® system received regulatory clearance for commercial use, opening the door to Latin America’s largest healthcare market and further reinforcing MicroPort® CardioFlow’s global strategy.
Meanwhile, in Ecuador, both the VitaFlow Liberty® system and the Alwide® Plus balloon catheter have obtained regulatory approval, enhancing the company’s presence and product availability in this region.
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation, HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic research and development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/